Related Experiment Videos
CD80 binding polyproline helical peptide inhibits T cell activation.
Mythily Srinivasan1, Debao Lu, Rajaraman Eri
1Department of Oral Pathology, School of Dentistry, 1121 W. Michigan St., Indianapolis 46202, USA. mysriniv@iupui.edu
The Journal of Biological Chemistry
|December 16, 2004
Summary
Novel peptide agents targeting CD80 offer potential therapeutic strategies by blocking T cell costimulatory molecule interactions. These CD80 competitive antagonists mimic natural binding sites to inhibit T cell activation and suppression.
Area of Science:
- Immunology
- Structural Biology
- Drug Discovery
Background:
- The CD28/CD152-CD80/CD86 costimulatory molecules are crucial for T cell activation and suppression, representing key therapeutic targets.
- CD28 and CD152 share a conserved polyproline motif, adopting a polyproline type II (PP) helical conformation essential for protein-protein interactions.
Purpose of the Study:
- To design novel peptide agents targeting the CD80 costimulatory molecule.
- To explore the therapeutic potential of these CD80 competitive antagonist peptides in modulating T cell responses.
Main Methods:
- Integrated analysis of interface amino acid contact preferences and propensity for PP(II) helix formation.
- Design of peptide agents derived from receptor binding sites to mimic bioactive conformations.
- Structural and functional studies of novel CD80 competitive antagonist peptides.
Main Results:
- Identified a conserved polyproline motif in CD28 and CD152 involved in ligand binding.
- Demonstrated that Pro(102) in CD152 influences PP(II) helix formation within the CD80-CD152 complex.
- Developed novel peptide agents designed to competitively antagonize CD80 binding.
Conclusions:
- Select CD80 competitive antagonist peptides show promise as therapeutic agents.
- Targeting the CD80 costimulatory pathway with peptide agents offers a viable strategy for immune modulation.